Amgen's Repatha lowered first heart attacks and strokes by 36% in a major trial, suggesting PCSK9 drugs may prevent acute ...

A new Merck pill called enlicitide slashes levels of harmful LDL cholesterol by up to 60%, similar to injectable PCSK9 drugs ...

In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions ...

Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® ...

The medication, which significantly lowers the risk of heart attacks, could be a promising alternative to expensive and ...

Multiple analyst firms were impressed by the Phase III data, which showed that Merck’s oral PCSK9 inhibitor can lower ...

The LDL-C reductions seen with enlicitide in both studies are in the same ballpark as those seen with injectable ...

Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer recently put under a microscope. Cramer showed quite a bullish ...

For some people with high cholesterol, making lifestyle changes and taking routine cholesterol-lowering statin medications may not be sufficient in helping them reach their target cholesterol levels.

The drug targets the PCSK9 protein, and could give millions of people a more affordable option to reduce their heart disease ...

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...